Pegylated liposomal doxorubicin in CHOP regimen for untreated elderly patients with advanced diffuse large B-cell lymphoma：re-sults from a prospective phase II study
10.3969/j.issn.1000-8179.20141732
- VernacularTitle:含聚乙二醇脂质体多柔比星的CHOP样方案治疗初治老年晚期弥漫大B细胞淋巴瘤的Ⅱ期临床研究
- Author:
Lin GUI
;
Yuankai SHI
;
Jianliang YANG
;
Peng LIU
;
Yan QIN
- Publication Type:Journal Article
- Keywords:
pegylated liposomal doxorubicin;
diffuse large B-cell lymphoma;
elderly;
cardiac toxicity
- From:
Chinese Journal of Clinical Oncology
2015;(3):162-166
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the efficacy and safety of pegylated liposomal doxorubicin (PLD) in CHOP regimen for un-treated elderly patients with advanced diffuse large B-cell lymphoma (DLBCL). Methods:In a prospective phase II study, we analyzed the feasibility of PLD-modified CHOP regimen in elderly patients with advanced stages of DLBCL. PLD was administered at 30 mg/m2 in combination with cyclophosphamide, vincristine, and prednisone at standard doses every 21 d for six cycles. CD20 positive patients were given option for rituximab treatment. Results:From November 2011 to March 2014, 30 patients with a median age of 70 years (range:63 to 80) were enrolled in this study. Up to 24 cases (80.0%) obtained an International Prognostic Index of≥3. The overall re-sponse rate was 86.7%, and the complete remission rate was 66.7%. With a median follow-up of 20.1 months, the 18-month overall and progression-free survival rates were 82.4%and 70.1%, respectively. The main toxicity was neutropenia, reaching grades 3 to 4 in the 24 cases (80.0%). No significant changes existed in patients' left ventricular ejection fraction and serum troponin-T during the study. Four patients (13.3%) showed asymptomatic abnormal changes in electrocardiogram after PLD infusion. Conclusion:CHOP regimen with PLD is an effective alternative for the treatment of DLBCL in elderly patients, exhibiting an acceptable toxicity.
